+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

India Intravenous Solutions Market Report and Forecast 2025-2034

  • PDF Icon

    Report

  • 200 Pages
  • July 2025
  • Region: India
  • Expert Market Research
  • ID: 6163014
The India intravenous solutions market size was valued at INR 171.44 Billion in 2024, driven by its wide utility in various healthcare domains ranging from surgical to post-surgical care across the region. The market is expected to grow at a CAGR of 8.30% during the forecast period of 2025-2034, with the values likely to rise from INR 380.54 Billion by 2034.

Intravenous Solutions: Introduction

Intravenous solutions are injected into a patient's vein to prevent or treat electrolyte imbalance or dehydration in the body. It is injected through an IV (intravenous) tube. It may be used to restore electrolytes in people who are suffering from diarrhea or vomiting, have exercised too much, have burns or serious injuries, or have undergone surgery. Intravenous solutions contain various nutrients. The three main types of intravenous solutions are hypotonic, isotonic, and hypertonic.

India Intravenous Solutions Market Analysis

The development of the healthcare infrastructure in the country is a key trend supporting the growth of the India intravenous solutions market value. With more hospitals and medical care centres available across the country, including in smaller towns, the demand for intravenous solutions is expected to rise. In addition, there is a heightened focus on providing apt neonatal care to decrease the infant mortality rate. As intravenous solutions provide instant effect, they have been widely adopted to treat malnutrition in infants, women as well as children in the region.

The rising prevalence of cancer is another factor contributing to the market growth. Treatments like radiation and chemotherapy also rely on intravenous solutions for efficient response.

Specific programs like the Rashtriya Kishor Swasthya Karyakram, Ayushman Bharat which includes PM-JAY, India's biggest government sponsored health insurance scheme, along with the National Digital Health Mission have been initiated by the government to make the masses informed and empowered to make appropriate health decisions. There is another allocation INR 5,000 crore to boost the medical healthcare research and development in pharmaceutical sector. Moreover, with the integration of latest technologies like artificial intelligence and data analytics in medical ecosystem, we can expect the India intravenous solutions market share to expand globally as well.

India Intravenous Solutions Market Segmentation

India Intravenous Solutions Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Type of Intravenous Solutions

  • Crystalloids
  • Colloids
  • Parenteral Nutrition Solutions
  • Blood-Derived Products
  • Others

Market Breakup by Application

  • Fluid Replacement Therapy
  • Electrolyte Imbalance Correction
  • Blood Transfusion
  • Parenteral Nutrition
  • Chemotherapy
  • Rehydration

Market Breakup by End-User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Home Healthcare Settings

India Intravenous Solutions Market Overview

India intravenous solutions market demand has observed a significant upswing, owing to their increased application in several healthcare conditions, including surgery, chemotherapy, blood transfusions as well as emergency medicines. This increased usage can be accredited to its relatively higher efficacy and rapid response capabilities to those in need. Moreover, the population dynamics of the region are quite diverse, ranging from pediatrics to geriatrics. Intravenous solutions, being easily accessible and affordable, are heavily used to cater to different dynamics.

India intravenous solutions market growth is driven by a diverse range of government as well as private sector initiatives to improve the healthcare system, build high-capacity hospitals and clinics for increasing population and facilitate better public health opportunities. In addition, there is high emphasis on inviting Foreign Direct Investment (FDI) with a vision to foster growth in the healthcare sector.

India Intravenous Solutions Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • Piramal Enterprises Limited
  • Hospira (Pfizer Inc.)
  • Amsino International Inc.
  • ICU Medical, Inc.
  • Sami Labs Limited
  • Troikaa Pharmaceuticals Ltd.
  • Neiss Labs Pvt. Ltd.
  • Ketan Pharma
  • Abaris Healthcare Pvt. Ltd.
  • Parenteral Drugs (India) Ltd.
  • Arbro Pharmaceuticals Limited
  • Neon Laboratories Ltd.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 India Intravenous Solutions Market Overview
3.1 India Intravenous Solutions Market Historical Value (2018-2024)
3.2 India Intravenous Solutions Market Forecast Value (2025-2034)
4 India Intravenous Solutions Market Landscape
4.1 India Intravenous Solutions Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 India Intravenous Solutions Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Applications
5 India Intravenous Solutions Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 India Intravenous Solutions Market Segmentation
6.1 India Intravenous Solutions Market by Type of Intravenous Solutions
6.1.1 Market Overview
6.1.2 Crystalloids
6.1.3 Colloids
6.1.4 Parenteral Nutrition Solutions
6.1.5 Blood-Derived Products
6.1.6 Others
6.2 India Intravenous Solutions Market by Application
6.2.1 Market Overview
6.2.2 Fluid Replacement Therapy
6.2.3 Electrolyte Imbalance Correction
6.2.4 Blood Transfusion
6.2.5 Parenteral Nutrition
6.2.6 Chemotherapy
6.2.7 Rehydration
6.3 India Intravenous Solutions Market by End-User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Clinics
6.3.4 Ambulatory Surgical Centres
6.3.5 Home Healthcare Settings
7 Patent Analysis
7.1 Analysis by Type of Patent
7.2 Analysis by Publication year
7.3 Analysis by Issuing Authority
7.4 Analysis by Patent Age
7.5 Analysis by CPC Analysis
7.6 Analysis by Patent Valuation
7.7 Analysis by Key Players
8 Grants Analysis
8.1 Analysis by year
8.2 Analysis by Amount Awarded
8.3 Analysis by Issuing Authority
8.4 Analysis by Grant Application
8.5 Analysis by Funding Institute
8.6 Analysis by NIH Departments
8.7 Analysis by Recipient Organization
9 Regulatory Framework
10 Suppliers Landscape
10.1 Baxter International Inc.
10.1.1 Financial Analysis
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 B. Braun Melsungen AG
10.2.1 Financial Analysis
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 Fresenius SE & Co. KGaA
10.3.1 Financial Analysis
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Piramal Enterprises Limited
10.4.1 Financial Analysis
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 Hospira (Pfizer Inc.)
10.5.1 Financial Analysis
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Amsino International Inc.
10.6.1 Financial Analysis
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 ICU Medical, Inc.
10.7.1 Financial Analysis
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Sami Labs Limited
10.8.1 Financial Analysis
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Troikaa Pharmaceuticals Ltd.
10.9.1 Financial Analysis
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Neiss Labs Pvt. Ltd.
10.10.1 Financial Analysis
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Ketan Pharma
10.11.1 Financial Analysis
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 Certifications
10.12 Abaris Healthcare Pvt. Ltd.
10.12.1 Financial Analysis
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.12.5 Certifications
10.13 Parenteral Drugs (India) Ltd.
10.13.1 Financial Analysis
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.13.5 Certifications
10.14 Arbro Pharmaceuticals Limited
10.14.1 Financial Analysis
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
10.14.5 Certifications
10.15 Neon Laboratories Ltd.
10.15.1 Financial Analysis
10.15.2 Product Portfolio
10.15.3 Demographic Reach and Achievements
10.15.4 Mergers and Acquisitions
10.15.5 Certifications
11 India Intravenous Solutions Market - Distribution Model (Additional Insight)
11.1 Overview
11.2 Potential Distributors
11.3 Key Parameters for Distribution Partner Assessment
12 Key Opinion Leaders (KOL) Insights (Additional Insight)
13 Company Competitiveness Analysis (Additional Insight)
13.1 Very Small Companies
13.2 Small Companies
13.3 Mid-Sized Companies
13.4 Large Companies
13.5 Very Large Companies
14 Payment Methods (Additional Insight)
14.1 Government Funded
14.2 Private Insurance
14.3 Out-of-Pocket